Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exclusivity For Biologics, Drugs Should Be The Same After All, Grabowski Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Duke University economics professor Henry Grabowski and his colleagues suggest the Hatch-Waxman statute be revised to mirror biosimilars legislation and provide 12 years of market exclusivity.

You may also be interested in...



Too Much Success for Generics? GPhA’s Neas Defends Hatch-Waxman

Newly installed GPhA CEO Ralph Neas has a lot to juggle these days on Capitol Hill, between drug shortages and user free agreements for generics and biosimilars. But one thing Neas wasn’t expecting was a threat to Hatch-Waxman. Has the generic drug industry become too successful for its own good?

GPhA’s Neas Preaches Vigilance Against Reopening Hatch-Waxman Act

After five months on the job, Generic Pharmaceutical Association President and CEO Ralph Neas is optimistic about the industry’s future but prepared to do battle against any efforts to re-work the landmark 1984 law. Preparations include establishing a new non-profit arm, the Affordable Medicine Research Institute, which will focus on research and public education about generics and biosimilars.

Pediatric Study Delays Could Draw Civil Penalties Under Proposal For PREA, BPCA Reauthorization

Civil penalties would be more flexible than FDA’s current authority to label a drug misbranded if sponsors fail to conduct pediatric studies, Commissioner Hamburg argues as the House Energy and Commerce Committee’s Health Subcommittee opens hearings on reauthorizing prescription drug user fees.

Related Content

Topics

UsernamePublicRestriction

Register

PS073016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel